Mammalian P-glycoproteins are active drug efflux transporters located in the plasma membrane. In the early nineties, we generated knockouts of the three P-glycoprotein genes of mice, the \textit{Mdr1a}, \textit{Mdr1b}, and \textit{Mdr2} P-glycoproteins, now known as \textit{Abcb1a}, \textit{Abcb1b}, and \textit{Abcb4}, respectively. In the \textit{JCI} papers that are the subject of this Hindsight, we showed that loss of \textit{Mdr1a} (\textit{Abcb1a}) had a profound effect on the tissue distribution and especially the brain accumulation of a range of drugs frequently used in humans, including dexamethasone, digoxin, cyclosporin A, ondansetron, domperidone, and loperamide. All drugs were shown to be excellent substrates of the murine ABCB1A P-glycoprotein and its human counterpart, the MDR1 P-glycoprotein, ABCB1. We found that the ability of ABCB1 to prevent accumulation of some drugs in the brain is a prerequisite for their clinical use, as absence of the transporter led to severe toxicity or undesired CNS pharmacodynamic effects. Subsequent work has fully confirmed the profound effect of the drug-transporting ABCB1 P-glycoprotein on the pharmacokinetics of drugs in humans. In fact, every new drug is now screened for transport by ABCB1, as this limits oral availability and penetration into sanctuaries protected by ABCB1, such as the brain.
Mammalian P-glycoproteins are active drug efflux transporters located in the plasma membrane. In the early nineties, we generated knockouts of the three P-glycoprotein genes of mice, the Mdr1a, Mdr1b, and Mdr2 P-glycoproteins, now known as Abcb1a, Abcb1b, and Abcb4, respectively. In the JCI papers that are the subject of this Hindsight, we showed that loss of Mdr1a (Abcb1a) had a profound effect on the tissue distribution and especially the brain accumulation of a range of drugs frequently used in humans, including dexamethasone, digoxin, cyclosporin A, ondansetron, domperidone, and loperamide. All drugs were shown to be excellent substrates of the murine ABCB1A P-glycoprotein and its human counterpart, the MDR1 P-glycoprotein, ABCB1. We found that the ability of ABCB1 to prevent accumulation of some drugs in the brain is a prerequisite for their clinical use, as absence of the transporter led to severe toxicity or undesired CNS accumulation of some drugs in the brain is a prerequisite for their clinical use, as absence of the transporter led to severe toxicity or undesired CNS pharmacokinetics, it was hard to get conclusive data, as the available inhibitors of P-glycoproteins were still toxic and not very specific. The knockout mice would fill that gap. We reduced the risk of getting scooped by generously explaining to our colleagues elsewhere that we had an edge and would get there first with the expert help of Anton Berns and his knockout crew. Apparently, the competition lost heart, and, in the end, we were the only lab to produce P-glycoprotein knockout mice.

A dead mouse with an unguarded blood-brain barrier
Before we were able to properly analyze the Mdr1a (Abcb1a) knockout mice, Schinkel received a message from our animal facility that his knockout mice were suddenly dying. When the animal caretakers were asked what they had done, their answer was predictably, “Nothing, we did nothing.” It soon emerged, however, that the mice had been sprayed with the pesticide ivermectin to counteract a mite infestation. A toxicity analysis demonstrated that the homozygous Mdr1a−/− mice were 100-fold more sensitive to ivermectin than their Mdr1a+/− littermates (2). Ivermectin is a strong neurotoxin, but normally it is kept out of the brains of mammals by ABCB1. In the Mdr1a−/− mice, about 100-fold more ivermectin accumulated in the brain, leading to lethal neurotoxicity.

This and subsequent work (3–7) established that a drug-transporting P-glycoprotein is an integral part of the blood-brain barrier (BBB) and essential in keeping large, hydrophobic drugs out of the brain. This conclusion was not directly accepted by scientists working on the BBB. Soon after the ivermectin mishap, Piet Borst was invited to address the European BBB Society as a late-breaking speaker. Before the talk, an established BBB researcher explained why large, amphipathic drugs were unable to pass the BBB, using purely chemical arguments, hydrogen bonds, etc. Borst then came with his disappointing message: it is not the subtle chemistry, but a pump that drives the drug from the apical membrane of the cerebral endothelium back into the circulation. This message was not well received. One discussant shouted in desperation, “Did you verify that every single capillary in the brain contains P-glycoprotein?” Of course we had not, but Borst explained that mice without MDR1A P-glycoprotein were “stone dead” after ivermectin administration, indicating that P-glycoprotein should be an essential component of the entire BBB.

The ABCB1 P-glycoprotein also limits uptake of some drugs from the gut
The presence of ABCB1 in the apical membrane of the intestine made it likely that this protein would also impede the uptake of the substrate drugs. It took time before this was proven and even longer before it became accepted that P-glycoprotein is a major factor in the oral availability of some substrate drugs. In fact, when we showed that the MDR1A P-glycoprotein impedes the uptake of digoxin from the gut (5), it was hard to get this ground-breaking result published. Acceptance improved when we obtained the same result for the anticancer drug paclitaxel. In that case, uptake of the drug is nearly completely prevented by P-glycoprotein, making it necessary to administer the drug intravenously (6). The demonstration that P-glycoprotein limits the oral availability of some drugs as well as their penetration into the brain has led to...
numerous attempts to eliminate this barrier by using increasingly specific P-glycoprotein inhibitors. P-glycoprotein has also become a buzzword in the pharma industry, as everybody prefers orally available drugs.

**Drug-transporting P-glycoprotein today**

As the ABCB1 P-glycoprotein is a highly versatile, if not promiscuous, drug transporter, the number of drugs affected by P-glycoprotein has exploded. The number of tissues specifically protected by P-glycoprotein has also increased, as illustrated in Figure 1. Whereas the role of P-glycoprotein in pharmacokinetics is large and undisputed, its role in drug resistance of human tumors has turned out to be much smaller than initially anticipated. There is no doubt that modest amounts of P-glycoprotein can completely protect mouse tumors from substrate drugs, such as taxanes or anthracyclines, but human tumors seem to use this effective defense mechanism only rarely (8).

**The knockout approach has been fruitful in pharmacology**

After our initial success, we made knockouts of many other transporter protein genes and combined some of these in double knockouts and triple knockouts. Schinkel concentrated on P-glycoprotein and Abcg2 and, more recently, on drug importers and P450
drug-metabolizing enzymes. Borst knocked out MRP2s (ABCCs) (9). Disrupting these genes has generated fundamental insight into the roles of these proteins in physiology and pharmacology. Obviously, eliminating the function of a gene in the germline can lead to secondary adjustments. Indeed, in 1994, we observed some upregulation of the second drug-transporting mouse P-glycoprotein gene, Abcb1b (Mdr1b), in the Mdr1a knockout (2). Thus far, however, these compensatory alterations have not affected the results of our knockout mice in a major way. We have never had reason to regret our entry into the transporter knockout field in 1990, and there is more to come.

Acknowledgments
We are grateful to the Dutch Cancer Society for their continued financial support of most of the work reviewed here. We also thank all our collaborators for their contributions and, especially, Els Wagenaar for her unrelenting dedication and success in generating the early knockout strains.

Address correspondence to: Piet Borst, Division of Molecular Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands. Phone: 31.20.512.2880; Fax: 31.20.669.1383; E-mail: p.borst@nki.nl.